Vimarsana
Biggest News Aggregation in the World

Page 3 - Ascending Dose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ascending Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ascending Dose Today - Breaking & Trending Today

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates - Vimarsana News

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates - Vimarsana News

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Synthetic Biologics Reports First Quarter 2022 Operational - Vimarsana News

Synthetic Biologics Reports First Quarter 2022 Operational

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive...

Crinetics Pharmaceuticals Reports First Quarter 2022 - Vimarsana News

Crinetics Pharmaceuticals Reports First Quarter 2022

Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated...

Liminal BioSciences Inc.: Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights - Vimarsana News

Liminal BioSciences Inc.: Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple